Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin.

Abstract

Hepatitis C virus (HCV) is the most common chronic infection in the United States, affecting almost 3.9 million Americans. The most effective treatment for chronic HCV infection is combination antiviral therapy with peginterferon and ribavirin. However, combination therapy is also associated with significant adverse effects and is contraindicated in certain patient populations. Hematological adverse effects are common and are a frequent cause of dose reduction and interruption or discontinuation of therapy. Currently there are no approved treatments for the hematological adverse events associated with HCV therapy. However, emerging data suggest that utilization of hematopoietic growth factors can provide a useful adjunct to treatment and optimize sustained virologic response rates.

• Authors: Nickolas Kontorinis, Kaushik Agarwal, Douglas T Dieterich
• Journal: Reviews in gastroenterological disorders (Rev Gastroenterol Disord) Vol. 4 Suppl 1 Pg. S39-47 ( 2004) ISSN: 1533-001X [Print] United States
• PMID: 15184822 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Erythropoietin
• Polyethylene Glycols
• Ribavirin
• Hepatocyte Growth Factor
• peginterferon alfa-2a

Topics

• Antiviral Agents (adverse effects, therapeutic use)
• Chemotherapy, Adjuvant
• Drug Therapy, Combination
• Erythropoietin (therapeutic use)
• Female
• Hepacivirus (drug effects, isolation & purification)
• Hepatitis C, Chronic (diagnosis, drug therapy, mortality)
• Hepatocyte Growth Factor (therapeutic use)
• Humans
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Male
• Polyethylene Glycols (therapeutic use)
• Recombinant Proteins
• Ribavirin (adverse effects, therapeutic use)
• Risk Assessment
• Severity of Illness Index
• Treatment Outcome
• Viral Load